MIRM ▲ +5.1% - Mirum Pharmaceuticals, Inc. $MIRM Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus 28-SEP-2026 08:01 AM ET